« Previous
Next »
Journal of the American Academy of Child & Adolescent Psychiatry
Volume 49, Issue 1
, Pages
13-23
, January 2010
Trends in Antipsychotic Drug Use by Very Young, Privately Insured Children
To access this article, please choose from the options below
This article is discussed in an editorial by Dr. Helen Egger on page 3.
This study was supported by AHRQ award U18 HS016097, the Center for Education and Research on Mental Health Therapeutics.
Disclosure: Dr. Olfson has received research support from Bristol Myers Squibb, AstraZeneca, and Eli Lilly & Company. He has served as a consultant for Pfizer and AstraZeneca. He has served on the speakers' bureau for Janssen. Drs. Crystal, Huang, and Gerhard report no biomedical financial interests or potential conflict of interest.
PII: S0890-8567(09)00005-7
doi: 10.1016/j.jaac.2009.09.003
© 2010 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
Journal of the American Academy of Child & Adolescent Psychiatry
Volume 49, Issue 1
, Pages
13-23
, January 2010
